Treatment with retinoid X receptor γ-selective ligand (bexarotene) may cause iatrogenic central hypothyroidism

European Journal of Endocrinology

Volumn 142, Issue 4, 2000, Pages 324-325

  Asteria, C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; LEVOTHYROXINE; LIOTHYRONINE; MESSENGER RNA; RETINOID X RECEPTOR; THYROID HORMONE RECEPTOR; THYROTROPIN; THYROXINE;

CLINICAL TRIAL; DRUG SELECTIVITY; HORMONE RECEPTOR INTERACTION; HORMONE RESPONSIVE ELEMENT; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; IATROGENIC DISEASE; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SKIN LYMPHOMA; T CELL LYMPHOMA; THYROTROPIN RELEASE;

EID: 0034015927     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1420324     Document Type: Short Survey

References (16)

1. Chatterjee VKK, Clifton-Bligh RJ & Gurnell M. Thyroid hormone resistance. In Contemporary Endocrinology: Hormone Resistance Syndromes, pp 145-163. Ed L Jameson. Totowa, NJ, USA: Humana Press Inc., 1999.
2. Kakizawa T, Miyamoto T, Kaneko A, Yajima H, Ichikawa K & Hashizume K. Ligand-dependent heterodimerization of thyroid hormone receptor and retinoid X receptor. Journal of Biological Chemistry 1997 272 23799-23804.
3. Mangelsdorf DJ, Borgmeyer U, Heyman RA, Zhou JY, Ong ES, Oro AE et al. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes and Development 1992 6 329-344.
4. Murray MB & Towle HC. Identification of nuclear factors that enhance binding of the thyroid hormone receptor to a thyroid hormone response element. Molecular Endocrinology 1989 3 1434-1442.
5. Lazar MA & Berrodin TJ. Thyroid hormone receptors form distinct nuclear protein-dependent and -independent complexes with a thyroid hormone response element. Molecular Endocrinology 1990 4 1627-1635.
6. Burnside J, Darling DS & Chin WW. A nuclear factor that enhances binding of thyroid hormone receptors to thyroid hormone response elements. Journal of Biological Chemistry 1990 265 2500-2504.
7. Haugen BR, Brown NS, Wood WM, Gordon DF & Ridgway EC. The thyrotrope-restricted isoform of the retinoid-X-rcceptor-γ1 mediates 9-cis-retinoic acid suppression of thyrotropin-β promoter activity. Molecular Endocrinology 1997 11 481-489.
8. Breen JJ, Matsuura T, Ross AC & Gurr JA. Regulation of thyroid-stimulating hormone beta-subunit and growth hormone messenger ribonucleic acid levels in the rat: effect of vitamin A status. Endocrinology 1995 136 543-549.
9. Coya R, Carro E, Mallo F & Dieguez C. Retinoic acid inhibits in vivo thyroid-stimulating hormone secretion. Life Science 1997 60 247-250.
10. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. Journal of Medical Chemistry 1994 37 2930-2941.
11. Lee HY, Dawson MI, Walsh GL, Nesbitt JC, Eckert RL, Fuchs E et al. Retinoic acid receptor and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells. Cell Growth and Differentiation 1996 7 997-1004.
12. Kizaki M, Dawson MI, Heyman R, Elster E, Morosetti R, Pakkala S et al. Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro. Blood 1996 87 1977-1984.
13. Gottardis MM, Bishoff ED, Shirley MA, Wagoner MA, Lamph WW & Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Research 1996 56 5566-5570.
14. Bischoff ED, Gottardis MM, Moon TE, Heyman RA & Lamph WW. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD 1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Research 1998 58 479-484.
15. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K. Nowlakha P et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. New England Journal of Medicine 1999 340 1075-1079.
16. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D et al. Initial clinical trial of a selective retinoid X receptor ligand LGD 1069. Journal of Clinical Oncology 1997 15 790-795.